Enhanced advanced glycosylation end product (AGE) formation has been shown to participate in the patho-genesis of diabetes-induced glomerular injury by mediating the increased extracellular matrix (ECM) deposition and altered cell growth and turnover leading to mesangial expansion. These effects could be exerted via an AGE-receptor-mediated upregulation of growth factors, such as the IGFs and transforming growth factor-β (TGF-β). We tested this hypothesis in human and rat mesangial cells grown on nonglycated or native bovine serum albumin (BSA), glycated BSA with AGE formation (BSA-AGE), or glycated BSA in which AGE formation was prevented by the use of aminoguanidine (BSA-AM), in the presence or absence of an antibody, α-p60, directed against the p60/OST protein named AGE-receptor 1 (AGE-R1), or normal control (pre-immune) serum. The mRNA and/or protein levels of IGF-I, IGF-II, IGF receptors, IGF binding proteins (IGFBPs), TGF-β1 and the ECM components fibronectin, laminin, and collagen IV were measured, together with cell proliferation. Both human and rat mesangial cells grown on BSA-AGE showed increased IGF-I and total and bioac-tive TGF-β medium levels and enhanced IGF-I, IGF-II, and TGF-β1 gene expression, compared with cells grown on BSA, whereas total IGFBP and IGFBP-3 medium content, IGF receptor density and affinity, and IGF-I receptor transcripts were unchanged. Moreover, cells grown on BSA-AGE showed increased ECM protein and mRNA levels versus cells cultured on BSA, whereas cell proliferation was unchanged in human mesangial cells and slightly reduced in rat mesangial cells. Growing cells on BSA-AM did not affect any of the measured parameters. Co-incubation of BSA-AGE with anti-AGE-R1, but not with pre-immune serum, prevented AGE-induced increases in IGF-I, TGF-β1, and ECM production or gene expression; anti-AGE-R1 also reduced growth factor and matrix synthesis in cells grown on BSA. These results demonstrate that mesangial IGF and TGF-β1 synthesis is upregulated by AGE-modified proteins through an AGE-receptor-mediated mechanism. The parallelism with increased ECM production raises the speculation that the enhanced synthesis of these growth factors resulting from advanced nonen-zymatic glycation participates in the pathogenesis of hyperglycemia-induced mesangial expansion.
Skip Nav Destination
Article navigation
Original Articles|
November 01 1997
Upregulation of Mesangial Growth Factor and Extracellular Matrix Synthesis by Advanced Glycation End Products Via a Receptor-Mediated Mechanism
Giuseppe Pugliese;
Giuseppe Pugliese
Department of Experimental Medicine, Chair of General Pathology, and 2nd Institute of Internal Medicine, Chairs of Endocrinology and Nephrology, La Sapienza University
Rome, Italy
Search for other works by this author on:
Flavia Pricci;
Flavia Pricci
Department of Experimental Medicine, Chair of General Pathology, and 2nd Institute of Internal Medicine, Chairs of Endocrinology and Nephrology, La Sapienza University
Rome, Italy
Search for other works by this author on:
Giulio Romeo;
Giulio Romeo
Department of Experimental Medicine, Chair of General Pathology, and 2nd Institute of Internal Medicine, Chairs of Endocrinology and Nephrology, La Sapienza University
Rome, Italy
Search for other works by this author on:
Francesco Pugliese;
Francesco Pugliese
Department of Experimental Medicine, Chair of General Pathology, and 2nd Institute of Internal Medicine, Chairs of Endocrinology and Nephrology, La Sapienza University
Rome, Italy
Search for other works by this author on:
Paolo Mené;
Paolo Mené
Department of Experimental Medicine, Chair of General Pathology, and 2nd Institute of Internal Medicine, Chairs of Endocrinology and Nephrology, La Sapienza University
Rome, Italy
Search for other works by this author on:
Stefano Giannini;
Stefano Giannini
Department of Clinical Pathophysiology, Chairs of Endocrinology, and 3rd Institute of Internal Medicine, University of Florence
Florence, Italy
Search for other works by this author on:
Barbara Cresci;
Barbara Cresci
Department of Clinical Pathophysiology, Chairs of Endocrinology, and 3rd Institute of Internal Medicine, University of Florence
Florence, Italy
Search for other works by this author on:
Gianna Galli;
Gianna Galli
Department of Clinical Pathophysiology, Chairs of Endocrinology, and 3rd Institute of Internal Medicine, University of Florence
Florence, Italy
Search for other works by this author on:
Carlo M Rotella;
Carlo M Rotella
Department of Clinical Pathophysiology, Chairs of Endocrinology, and 3rd Institute of Internal Medicine, University of Florence
Florence, Italy
Search for other works by this author on:
Helen Vlassara;
Helen Vlassara
Picower Institute for Medical Research
Manhasset, New York
Search for other works by this author on:
Umberto Di Mario
Umberto Di Mario
Department of Clinical and Experimental Medicine, Chair of Endocrinology, University of Reggio Calabria
Catanzaro, Italy
Search for other works by this author on:
Address correspondence and reprint request to Dr. Giuseppe Pugliese, Diabetes, Endocrinology, and Metabolism Foundation, Largo Marchiafava 1, 00161 Rome, Italy.
Diabetes 1997;46(11):1881–1887
Article history
Received:
December 23 1996
Revision Received:
July 11 1997
Accepted:
July 11 1997
PubMed:
9356040
Citation
Giuseppe Pugliese, Flavia Pricci, Giulio Romeo, Francesco Pugliese, Paolo Mené, Stefano Giannini, Barbara Cresci, Gianna Galli, Carlo M Rotella, Helen Vlassara, Umberto Di Mario; Upregulation of Mesangial Growth Factor and Extracellular Matrix Synthesis by Advanced Glycation End Products Via a Receptor-Mediated Mechanism. Diabetes 1 November 1997; 46 (11): 1881–1887. https://doi.org/10.2337/diab.46.11.1881
Download citation file:
91
Views